Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Early identification of aggressive papillary thyroid cancer (PTC) is crucial for effective treatment.
• Disease dissemination significantly impacts patient survival in PTC.
• The BRAF V600E mutation is a known indicator of recurrence, but its role in PTC dissemination requires further investigation.

Purpose of the Study:

• To investigate the association between BRAF V600E allele frequency and disease dissemination in papillary thyroid cancer.
• To explore the correlation of BRAF V600E mutation with PTC aggressiveness and angioinvasion.

Main Methods:

• Analysis of 173 PTC samples using quantitative PCR (qPCR) to measure BRAF V600E allele proportion.
• Normalization of BRAF V600E allele frequency against tumor cell proportion.
• Semiquantitative assessment of BRAF V600E mutant protein via immunohistochemistry.

Main Results:

• The BRAF V600E mutation was detected in 60% of PTC samples.
• Normalized BRAF V600E allele frequency varied widely, from 1.55% to 92.06%.
• No significant association was found between BRAF V600E mutation presence/proportion and PTC dissemination.
• A significant link was observed between the presence of the BRAF mutation and angioinvasion.

Conclusions:

• The BRAF V600E mutation alone may not be a primary driver of papillary thyroid cancer aggressiveness.
• Results indicate a heterogeneous distribution of the BRAF mutation and potential oligoclonal nature of PTC.
• Further research is needed to fully elucidate the role of BRAF mutations in PTC progression and dissemination.